The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.

Although the risk of severe SFI flare was higher with belimumab versus placebo in the BLyS mRNA low subgroup, the difference did not reach statistical significance (HR 1.24; 95% CI 0.61, 2.51; p = 0.5576; Fig. 4 a–c; Additional file 7 : Table S5).

also in 111,027 other papers